MaxCyte and Vittoria Biotherapeutics Partner to Propel Next-Generation Cellular Therapies through Strategic Platform License
11 July 2023
Collaborations, Mergers & Acquisitions
MaxCyte and Vittoria have recently signed a strategic platform license agreement for MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. Vittoria is now able to use these technologies for clinical and commercial purposes on a non-exclusive basis. MaxCyte will receive platform licensing fees and program-related revenue as part of the agreement.
The leading cell-engineering-focused company, MaxCyte, Inc., and leading-edge gene-edited cell therapeutics company, Vittoria Biotherapeutics, Vittoria, will be advancing next-generation cellular therapies. MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology, designed to address current gaps with current cell therapies.
Vittoria is set to submit an IND for their lead program, Viper 101, this year. To address unmet needs in treating T-cell lymphoma, MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will provide valuable support. Viper 101 is a gene-edited, autologous, dual-population cell therapy that uses Vittoria’s proprietary Senza5™ technology to enhance CAR-T treatments’ viability, efficacy, and safety. It achieves this by modulating a novel checkpoint pathway in engineered T-cells.
Nicholas Siciliano, Ph.D., CEO of Vittoria stated:
“MaxCyte’s experience with clinical grade manufacturing of gene-edited cellular therapeutics will greatly enhance the robustness and reproducibility of our manufacturing process, ensuring that each batch of our CAR-T cells meets the highest standards of consistency and quality.”
Vittoria’s Senza5™ CAR-T cells have demonstrated superior anti-tumor efficacy in liquid and solid tumor preclinical models and employ a proprietary five-day manufacturing process.
MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically validated electroporation technology for complex and scalable cell engineering, delivering high-end performance through transfection efficiency, seamless scalability and enhanced functionality.
“Through our partnership with Vittoria, MaxCyte has gained an opportunity to further validate and showcase our technology in a real-world setting and expand its footprint in the promising field of CAR-T therapies. We look forward to supporting Vittoria’s efforts to improve efficacy and enhance safety of T-cell therapies.” said Doug Doerfler, President and CEO of MaxCyte.